Fortrea Holdings Inc (FTRE) Stock
Key stats
- Market cap
- $2.27B
- Price / Earnings ratio
- -26.9x
- EPS (TTM)
- -$11.38
- Volume
- Loading
- 52-week high
- $24.37
- 52-week low
- $8.55
- EPS vs analyst estimate
- -25.0%Q3 FY25 · $0.12 vs $0.16
- Next earnings report
- 4 Nov 2026
Source: third-party data provider, as of October 24, 2026
EPS estimate: analyst consensus
Compare with FTRE
Recent news

Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?
Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?
FTRE

Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know
Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know
FTRE

FTRE vs. ARGX: Which Stock Is the Better Value Option?
FTRE vs. ARGX: Which Stock Is the Better Value Option?
FTRE

Best Momentum Stock to Buy for July 31st
Best Momentum Stock to Buy for July 31st
FTRE
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 73.54
- MACD 12/26/9
- 1.10
- EMA 9 of MACD
- 0.84
- MACD histogram
- 0.26
- SMA 50
- $19.58
- Price above SMA 50
- EMA 50
- $20.08
- Price above EMA 50
- SMA 200
- $15.51
- Price above SMA 200
- EMA 200
- $16.28
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.21 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?
Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?
FTRE

Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know
Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Know
FTRE

FTRE vs. ARGX: Which Stock Is the Better Value Option?
FTRE vs. ARGX: Which Stock Is the Better Value Option?
FTRE

Best Momentum Stock to Buy for July 31st
Best Momentum Stock to Buy for July 31st
FTRE

Fortrea Holdings Inc. (FTRE) Is Attractively Priced Despite Fast-paced Momentum
Fortrea Holdings Inc. (FTRE) Is Attractively Priced Despite Fast-paced Momentum
FTRE

Fortrea Q2 Earnings Call Highlights
Fortrea Q2 Earnings Call Highlights
FTRE

Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue Estimates
Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue Estimates
FTRE

Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm
Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm
FTRE

Stocks Look Shaky, But This Sector is Booming (Biotech)
Stocks Look Shaky, But This Sector is Booming (Biotech)
FTRE

FTRE or ARGX: Which Is the Better Value Stock Right Now?
FTRE or ARGX: Which Is the Better Value Stock Right Now?
FTRE
News tone: automated (AI) classification of the article's content, not a price prediction.
About Fortrea Holdings Inc
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Anshul Thakral | CEO & Director | 1978 |
| Mr. Mark A. Morais | COO & President of Clinical Services | 1977 |
| Mr. Jason F. Knoblauch | Chief Financial Officer | 1981 |
| Ms. Jill McConnell | Executive Officer | 1974 |
| Mr. Drayton Virkler | President & Chief Commercial Officer | — |
| Ms. Carrie Russell | VP of Accounting & Chief Accounting Officer | — |
| Mr. Alejandro Martinez Galindo | Chief Information Officer | — |
| Mr. Dave Cooper | Chief Administrative Officer | — |
| Ms. Tracy H. Krumme | Senior VP of Investor Relations | 1968 |
| Ms. Agnieszka M. Gallagher J.D. | General Counsel & Corporate Secretary | 1974 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 24, 2026
Technical indicators
- RSI 14
- 73.54
- MACD 12/26/9
- 1.10
- EMA 9 of MACD
- 0.84
- MACD histogram
- 0.26
- SMA 50
- $19.58
- Price above SMA 50
- EMA 50
- $20.08
- Price above EMA 50
- SMA 200
- $15.51
- Price above SMA 200
- EMA 200
- $16.28
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $22.00
- Average
- $24.00
- High
- $26.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | -13.2 | -10.6 | +5.2 | +2.4 | +4.2 | +12.1 | ||||||
| 2024 | -10.2 | +21.0 | +6.4 | -8.5 | -31.6 | -6.1 | +15.6 | -17.2 | -9.7 | -14.4 | +24.9 | -14.3 |
| 2025 | -9.9 | -11.6 | -27.3 | -11.6 | -29.3 | +19.6 | +10.2 | +80.4 | -15.9 | +9.9 | +25.6 | +38.7 |
| 2026 | +0.0 | -36.4 | -10.8 | +20.9 | +26.4 | +10.4 | +9.0 | -3.0 | +12.6 | +23.3 |



